Wednesday, February 27, 2019

Financial News Conference Full Year 2018 results

Location: Leverkusen, Baykomm (Bayer‘s Communication Center)

Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros
EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros
Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings
Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline
Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start
Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits
Net income at 1.695 billion euros, impacted by one-time effects
Core earnings per share at 5.94 euros, above expectations
Net financial debt at 35.679 billion euros, significantly better than expected
Bayer confirms 2019 Group outlook and 2022 targets

Links

Annual Report 2018

Recording of the Conference

Speaker